{"schema_version":"secwatch.filing_event.v1","accession":"0001070081-25-000018","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.411660+00:00","generated_at":"2026-05-22T10:41:00.965076+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PTC Therapeutics Q1 net income $866.6M on Novartis deal; guides FY revenue $650-800M","bullets":["Net income $866.6M vs loss $91.6M YoY, driven by $986.2M upfront from Novartis PTC518 license deal.","Total net product & royalty revenue $189.9M; DMD franchise (Translarna+Emflaza) $134M, down YoY.","Cash, equivalents & marketable securities $2.027B as of March 31, 2025, up from $1.14B at Dec 31, 2024.","Positive CHMP opinion for Sephience (sepiapterin) in PKU; NDA under FDA review with PDUFA July 29, 2025.","PTC518 Phase 2 PIVOT-HD met primary endpoint of dose-dependent blood HTT lowering; plans to discuss accelerated approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001070081-25-000018","json":"https://secwatch.observer/filing/0001070081-25-000018.json","markdown":"https://secwatch.observer/filing/0001070081-25-000018.md","text":"https://secwatch.observer/filing/0001070081-25-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000107008125000018/0001070081-25-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000107008125000018/tmb-20250506x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T10:41:00.965076+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}